Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

DNA damage response inhibitors enhance tumour treating fields (TTFields) potency in glioma stem-like cells

30 Sept 2023

Abstract excerpt

BACKGROUND: High-grade gliomas are primary brain cancers with unacceptably low and persistent survival rates of 10-16 months for WHO grade 4 gliomas over the last 40 years, despite surgical resection and DNA-damaging chemo-radiotherapy. More recently, tumour-treating fields therapy (TTFields) has demonstrated modest survival benefit and been clinically approved in several countries. TTFields is thought to mediate...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Repair Mechanisms
Share to Glioma Diagnosis and Treatment
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37777579
DOI: 10.1038/s41416-023-02454-0

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

DNA damage response inhibitors enhance tumour treating fields (TTFields) potency in glioma stem-like cellsPMID 37777579Read ↗

MGMT function determines the differential response of ATR inhibitors with DNA-damaging agents in glioma stem cells for GBM therapySemantic proximity Read ↗

Selective Inhibition of Parallel DNA Damage Response Pathways Optimizes Radiosensitization of Glioblastoma Stem-like CellsSemantic proximity Read ↗

Therapeutic targeting of constitutive PARP activation compromises stem cell phenotype and survival of glioblastoma-initiating cells.Semantic proximity Read ↗

Chronically radiation-exposed survivor glioblastoma cells display poor response to Chk1 inhibitionSemantic proximity Read ↗

Ex-vivo drug screening of surgically resected glioma stem cells to replace murine avatars and provide personalise cancer therapy for glioblastoma patientsSemantic proximity Read ↗

G-quadruplex ligand RHPS4 radiosensitizes glioblastoma xenograft in vivo through a differential targeting of bulky differentiated- and stem-cancer cellsSemantic proximity Read ↗

Combining the DNA Repair Inhibitor Dbait With Radiotherapy for the Treatment of High Grade Glioma: Efficacy and Protein Biomarkers of Resistance in Preclinical ModelsSemantic proximity Read ↗

The transcriptomic fingerprint of cancer response to Tumor Treating Fields (TTFields)Semantic proximity Read ↗

Overcoming Resistance of Glioblastoma to Conventional Cytotoxic Therapies by the Addition of PARP InhibitorsSemantic proximity Read ↗

Proton beam radiation induces DNA damage and cell apoptosis in glioma stem cells through reactive oxygen speciesSemantic proximity Read ↗

G-quadruplex DNA drives genomic instability and represents a targetable molecular abnormality in ATRX-deficient malignant gliomaSemantic proximity Read ↗

Radiogenomics of Stereotactic Radiotherapy: Genetic Mechanisms Underlying Radiosensitivity, Resistance, and Immune ResponseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.